Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Allarity Therapeutics, Inc. (ALLR) has issued an update.
Allarity Therapeutics, Inc. has announced exciting progress in its Phase 2 clinical trial for stenoparib, revealing that several patients with advanced recurrent ovarian cancer have been successfully treated for over 30 weeks. This milestone indicates promising potential for the drug and showcases the company’s commitment to advancing cancer treatment.
For an in-depth examination of ALLR stock, go to TipRanks’ Stock Analysis page.